My Cart

Angiopoietin-like 3

Angiopoietin-like 3 Overview

English NameAngiopoietin like 3Approved Drugs1
Drugs in Clinical Trials14Target SynonymAngiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
Highest Development StageApproved
English NameAngiopoietin like 3
Target SynonymAngiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
Approved Drugs1
Drugs in Clinical Trials14
Highest Development StageApproved

Angiopoietin-like 3 Product List

  • Product Category

    Protein (5)

  • Product Status

    Launched (5)

  • Species

    Human (4)Mouse (1)

  • Tag

    His Tag (3)His Tag & Avi Tag (1)Fc Tag (1)

  • Conjugate

    Unconjugated (4)Biotin-labeled (1)

Angiopoietin-like 3 Background

Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Angiopoietin-like 3 Synonyms

ANGPTL3,ANGPT5,ANG-5,Angiopoietin-5,FHBL2

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
ZodasiranARO-ANG3; ARO-ANG33; VSA-003 (Arrowhead Pharmaceuticals)Phase 3 ClinicalRoche LtdDyslipidemias; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipoproteinemia Type II; Hypertriglyceridemia
Details
LNA-043LNA-043Phase 2 ClinicalNovartis Pharma AgKnee Injuries; Osteoarthritis; Osteoarthritis, Knee
Details
VupanorsenISIS-703802; PF-07285557Phase 2 ClinicalIonis Pharmaceuticals IncCardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Homozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
Details
EDP-167EDP-167; EDP167Phase 2 ClinicalEteng Pharmaceutical (Zhuhai) Co LtdDyslipidemias; Homozygous familial hypercholesterolemia
Details
ALN-ANG3ALN-ANG3Phase 2 ClinicalAlnylam Pharmaceuticals IncDiabetic Nephropathies
Details
BW-00112BW-00112; BW00112Phase 2 ClinicalShanghai Argo Biopharmaceutical Co LtdDyslipidemias; Hypertriglyceridemia
Details
SolbinsiranLY-3561774; DCR-CM-1; DCR-CM1Phase 2 ClinicalDicerna Pharmaceuticals IncCardiovascular Diseases; Dyslipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases
Details
JS-401JS-401; RP-912Phase 1 ClinicalRisen (Suzhou) Pharma Tech Co LtdHyperlipidemias; Metabolic Diseases
Details
VERVE-201VERVE-201Phase 1 ClinicalBroad Institute, Harvard UniversityAtherosclerosis; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia
Details
SYH-2070SYH2070; SYH-2070Phase 1 ClinicalCspc Heibei Zhongrun Pharmaceutiacl Co LtdHyperlipidemia, Familial Combined; Hyperlipidemias; Hypertriglyceridemia
Details
NN-6491NN6491; NN-6491Phase 1 ClinicalNovo Nordisk A/SCardiovascular Diseases
Details
NNC0491-6075NNC0491-6075; NNC04916075Phase 1 ClinicalNovo Nordisk A/SDyslipidemias
Details
AZD-1705AZD1705; AZD-1705Phase 1 ClinicalAstrazeneca Plc, Parexel International CorpCardiovascular Diseases
Details
CTX-310CTX-310; CTX310Phase 1 ClinicalCrispr Therapeutics AgCardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases; Sitosterolemia
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
EvinacumabREGN-1500ApprovedRegeneron Pharmaceuticals IncEvkeezaUnited StatesHypercholesterolemia; Homozygous familial hypercholesterolemiaRegeneron Pharmaceuticals Inc2021-02-11Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia; Metabolic Diseases
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland